-
Mashup Score: 3Pembrolizumab With Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Hodgkin Lymphoma - 1 year(s) ago
This nonrandomized clinical trial investigates the addition of pembrolizumab to ifosfamide, carboplatin, and etoposide chemotherapy and evaluates the response rate of patients with relapsed or refractory Hodgkin lymphoma.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet
Pembrolizumab + Ifosfamide, Carboplatin & Etoposide [ICE] Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: Multi-institutional Phase 2 Investigator-Initiated Non-RCT [Mar 16, 2023] Bryan et al. @JAMAOnc https://t.co/KXrYTyuQH4 #NCT03077828 #lymsm